CN101448791B - Fxr激动剂 - Google Patents
Fxr激动剂 Download PDFInfo
- Publication number
- CN101448791B CN101448791B CN2007800182169A CN200780018216A CN101448791B CN 101448791 B CN101448791 B CN 101448791B CN 2007800182169 A CN2007800182169 A CN 2007800182169A CN 200780018216 A CN200780018216 A CN 200780018216A CN 101448791 B CN101448791 B CN 101448791B
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- isopropyl
- pyrazol
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BXKXNHBJSHXOBE-UHFFFAOYSA-N CC(C)c1c(COc(cc2)cc(C)c2NCc2cccc(C(O)=O)c2)[n](-c(c(Cl)ccc2)c2Cl)nc1 Chemical compound CC(C)c1c(COc(cc2)cc(C)c2NCc2cccc(C(O)=O)c2)[n](-c(c(Cl)ccc2)c2Cl)nc1 BXKXNHBJSHXOBE-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1cc(OCc2c(C3CC3)cn[n]2-c(cccc2)c2OC(F)(F)F)ccc1N(C)Cc1ccc(C(*)=N)c(OC)c1 Chemical compound Cc1cc(OCc2c(C3CC3)cn[n]2-c(cccc2)c2OC(F)(F)F)ccc1N(C)Cc1ccc(C(*)=N)c(OC)c1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80292006P | 2006-05-24 | 2006-05-24 | |
| US60/802,920 | 2006-05-24 | ||
| US86999506P | 2006-12-14 | 2006-12-14 | |
| US60/869,995 | 2006-12-14 | ||
| PCT/US2007/069445 WO2007140183A1 (en) | 2006-05-24 | 2007-05-22 | Fxr agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101448791A CN101448791A (zh) | 2009-06-03 |
| CN101448791B true CN101448791B (zh) | 2011-11-16 |
Family
ID=42827365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800182169A Expired - Fee Related CN101448791B (zh) | 2006-05-24 | 2007-05-22 | Fxr激动剂 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7846960B2 (enExample) |
| EP (1) | EP2029547B1 (enExample) |
| JP (1) | JP5119241B2 (enExample) |
| CN (1) | CN101448791B (enExample) |
| AT (1) | ATE465996T1 (enExample) |
| AU (1) | AU2007267606A1 (enExample) |
| BR (1) | BRPI0712262A2 (enExample) |
| CA (1) | CA2651378C (enExample) |
| DK (1) | DK2029547T3 (enExample) |
| EA (1) | EA015632B9 (enExample) |
| MX (1) | MX2008014854A (enExample) |
| PL (1) | PL2029547T3 (enExample) |
| WO (1) | WO2007140183A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100017372A (ko) * | 2007-05-25 | 2010-02-16 | 애보트 게엠베하 운트 콤파니 카게 | 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물 |
| TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009086277A1 (en) | 2007-12-20 | 2009-07-09 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| EA022417B1 (ru) * | 2008-10-21 | 2015-12-30 | Саймабэй Терапевтикс, Инк. | Арильные агонисты рецептора gpr120 и их применение |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8252826B2 (en) | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ａｍｐｋを活性化させるインダゾール化合物 |
| MX377523B (es) | 2013-09-11 | 2025-03-10 | Inst Nat Sante Rech Med | Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b. |
| SG11201603026PA (en) | 2013-11-05 | 2016-05-30 | Novartis Ag | Compositions and methods for modulating farnesoid x receptors |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| ES2905872T3 (es) | 2015-02-06 | 2022-04-12 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapia combinada |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| RU2712099C2 (ru) | 2015-03-31 | 2020-01-24 | Энанта Фармасьютикалс, Инк. | Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения |
| CN107613986A (zh) | 2015-04-07 | 2018-01-19 | 英特塞普特医药品公司 | 用于组合疗法的药物组合物 |
| US10351576B2 (en) | 2015-04-30 | 2019-07-16 | Novartis Ag | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors |
| TWI724077B (zh) * | 2015-12-16 | 2021-04-11 | 日商日本曹達股份有限公司 | 芳基唑化合物及有害生物防除劑 |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) * | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| JP6915050B2 (ja) * | 2016-09-14 | 2021-08-04 | ノバルティス アーゲー | Ｆｘｒアゴニストの新規のレジーム |
| CA3039124A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
| JP7618384B2 (ja) | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| ES2982801T3 (es) | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas |
| JP2020515564A (ja) | 2017-03-30 | 2020-05-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物 |
| RU2741306C1 (ru) | 2017-04-12 | 2021-01-25 | Ил Дон Фармасьютикал Ко., Лтд. | Производные изоксазола в качестве агонистов ядерных рецепторов и их применение |
| KR102731925B1 (ko) | 2017-11-01 | 2024-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물 |
| US11286252B2 (en) | 2017-11-01 | 2022-03-29 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| US11168079B2 (en) | 2017-11-01 | 2021-11-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| CN108299405A (zh) * | 2018-02-12 | 2018-07-20 | 李化绪 | 3-对n,n二乙基氨基苯基亚氨基类化合物及其在高脂血症药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| EP3807254A4 (en) | 2018-06-18 | 2022-03-23 | Epigen Biosciences, Inc. | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES |
| KR102692309B1 (ko) | 2019-01-15 | 2024-08-07 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| WO2020172075A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US20220226350A1 (en) | 2019-05-30 | 2022-07-21 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| CN110878052B (zh) * | 2019-12-11 | 2021-05-07 | 山东大学 | 一种含有fxr激动剂的化合物及其制备方法和应用 |
| WO2021122645A1 (en) | 2019-12-20 | 2021-06-24 | Syngenta Crop Protection Ag | Pesticidally active azole-amide compounds |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists for treating an infection by hepatitis d virus |
| MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
| TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
| JP7760117B2 (ja) * | 2021-08-23 | 2025-10-27 | 大学共同利用機関法人情報・システム研究機構 | オーキシンデグロンシステムのキット、及びその使用 |
| CN119462450B (zh) * | 2024-12-02 | 2026-05-29 | 西安近代化学研究所 | 一种双三氟甲基硫醚的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| DE60131967D1 (de) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| JP2006515838A (ja) * | 2002-11-22 | 2006-06-08 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| US7507832B2 (en) | 2003-12-22 | 2009-03-24 | Eli Lilly And Company | Triazole PPAR modulators |
-
2007
- 2007-05-22 DK DK07797648.8T patent/DK2029547T3/da active
- 2007-05-22 AU AU2007267606A patent/AU2007267606A1/en not_active Abandoned
- 2007-05-22 JP JP2009512259A patent/JP5119241B2/ja active Active
- 2007-05-22 MX MX2008014854A patent/MX2008014854A/es active IP Right Grant
- 2007-05-22 CA CA2651378A patent/CA2651378C/en not_active Expired - Fee Related
- 2007-05-22 AT AT07797648T patent/ATE465996T1/de active
- 2007-05-22 EP EP07797648A patent/EP2029547B1/en active Active
- 2007-05-22 WO PCT/US2007/069445 patent/WO2007140183A1/en not_active Ceased
- 2007-05-22 CN CN2007800182169A patent/CN101448791B/zh not_active Expired - Fee Related
- 2007-05-22 PL PL07797648T patent/PL2029547T3/pl unknown
- 2007-05-22 EA EA200870570A patent/EA015632B9/ru not_active IP Right Cessation
- 2007-05-22 US US12/296,534 patent/US7846960B2/en active Active
- 2007-05-22 BR BRPI0712262-4A patent/BRPI0712262A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2651378C (en) | 2012-08-28 |
| WO2007140183A1 (en) | 2007-12-06 |
| BRPI0712262A2 (pt) | 2012-07-10 |
| AU2007267606A1 (en) | 2007-12-06 |
| JP2009538335A (ja) | 2009-11-05 |
| CA2651378A1 (en) | 2007-12-06 |
| CN101448791A (zh) | 2009-06-03 |
| JP5119241B2 (ja) | 2013-01-16 |
| EP2029547A1 (en) | 2009-03-04 |
| MX2008014854A (es) | 2008-12-05 |
| ATE465996T1 (de) | 2010-05-15 |
| US7846960B2 (en) | 2010-12-07 |
| DK2029547T3 (da) | 2010-07-26 |
| PL2029547T3 (pl) | 2010-09-30 |
| EA200870570A1 (ru) | 2009-04-28 |
| EA015632B1 (ru) | 2011-10-31 |
| US20090270460A1 (en) | 2009-10-29 |
| EP2029547B1 (en) | 2010-04-28 |
| EA015632B9 (ru) | 2012-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5119241B2 (ja) | Ｆｘｒアゴニスト | |
| JP5225984B2 (ja) | Ｆｘｒを調節する化合物及び方法 | |
| JP4573133B2 (ja) | ピロリジン誘導体またはその塩 | |
| TWI504589B (zh) | 作為香草類化合物受體之配體之經取代芳香族羧醯胺及尿素衍生物 | |
| CN101374834B (zh) | 用于调节fxr的化合物和方法 | |
| ES2457521T3 (es) | Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coA desaturasa | |
| CN100467443C (zh) | 作为纤溶酶原激活物抑制剂1型(pai-1)的6-(芳基-酰氨基或芳基-酰氨甲基)-萘-2-基氧基-酸衍生物 | |
| WO2007129745A1 (ja) | ヘテロアリールアミド低級カルボン酸誘導体 | |
| JP2010513398A (ja) | ステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）阻害薬としてのイソキノリンカルボキサミド誘導体 | |
| WO2001002349A1 (en) | Phenyl sulfamate derivatives | |
| CN105431416A (zh) | 4-炔基咪唑衍生物和含有其作为有效成分的药物 | |
| WO1997037970A1 (en) | Phenylalkylcarboxylic acid derivatives | |
| WO2006095713A1 (ja) | プラスミノゲンアクチベータインヒビター－１阻害剤 | |
| CA2550187C (en) | Non-nucleoside reverse transcriptase inhibitors | |
| KR20050033663A (ko) | 비-뉴클레오시드 역전사효소 억제제 | |
| CN101448798A (zh) | 用于调节fxr的化合物和方法 | |
| HK40105408A (en) | Tead inhibitors | |
| CN1926108B (zh) | 非核苷酸逆转录酶抑制剂 | |
| ES2342222T3 (es) | Agonistas de fxr. | |
| CN102791695B (zh) | 作为fxr调节剂的环戊基-和环庚基吡唑类 | |
| CN101365680A (zh) | 作为肾素抑制剂的3,5-取代的哌啶化合物 | |
| HK1191005A (en) | Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease | |
| HK1101400B (en) | Non-nucleotide reverse transcriptase inhibitors | |
| HK1182101B (en) | Triazole derivatives as ligands for gaba receptors | |
| HK1182101A1 (en) | Triazole derivatives as ligands for gaba receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111116 Termination date: 20120522 |